MA-IBASIS
14.5.2024 14:01:39 CEST | Business Wire | Press release
iBASIS, the leading provider of communications solutions for operators and digital players worldwide, and Altice Dominicana, one of the leading mobile networks in the Dominican Republic, announced today that they have renewed their successful outsourcing agreement for voice services.
Since its sale by Altice in 2018, iBASIS and its global team have been dedicated to bringing Altice Dominicana best-in-class services, leveraging the group consolidation and economy of scale strategy of its owner, Tofane Global. iBASIS has helped to drive the Dominican operator’s performance, monetization, and profitability through its differentiated model, international expertise, and exclusive Inbound Gateway. Key focus areas, including cost improvement and fraud prevention, have also played a pivotal role in supporting Altice Dominicana’s sustained traffic growth.
“iBASIS demonstrated their commitment to deliver value across many facets of our international business. Their offerings and expertise, specifically in addressing international requirements, enable us to make significant service quality enhancements and cost improvements,” said Jennifer Espinal, International Business Manager at Altice Dominicana. “The strategic relationship, including the exclusive Inbound Gateway, is essential for maintaining our growth trajectory and securing our leading position in the region. We are also fortifying this collaboration and expanding into mobile services in order to capitalize on the growth of inbound roaming traffic.”
The Dominican Republic has experienced remarkable growth in tourism, witnessing a 14% increase in international visitors in 2023 compared to 2019, surpassing 10 million travelers for the first time.* Ensuring excellent roaming performance and experience is crucial in such an appealing destination for foreign visitors.
“With Altice Dominicana, we share the same goal of providing state-of-the-art connectivity and supporting innovations to unleash the potential of international communications,” said Edwin van Ierland, CEO of Voice & Mobile Data at iBASIS. “Thanks to our global platforms, capabilities, and highly motivated teams, iBASIS is a high-growth partner and is helping Altice Dominicana to continue to perform at the highest level.”
“The renewal with Altice Dominicana marks another significant milestone, highlighting the appeal of iBASIS's outsourcing proposition," remarked Alexandre Pébereau, Group CEO and Founder of Tofane Global. "By overseeing the entire spectrum of international voice and mobile communications for them, our customers can concentrate on their retail business, foster growth, and sustain their dominant market position.”
ABOUT iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist and Tier One IPX vendor with 800+ LTE destinations. iBASIS today serves 1,000+ customers across 28 locations worldwide. iBASIS optimizes global connectivity, quality, and security so customers achieve high return on voice, SMS A2P messaging, mobile data, 5G roaming, and IoT. iBASIS provides the end-to-end Global Access for Things™ connectivity solution, delivering single source cellular IoT access (LTE, LTE-M and NB-IoT) worldwide provisioned through GSMA-standard eSIM/eUICC technology. For more information, please visit iBASIS.com.
ABOUT Altice Dominicana
Altice Dominicana is one of the main telecommunications companies in the Dominican Republic, with a decade-long history of offering connectivity and entertainment services.
Its robust mobile network has 98% coverage nationwide; With an extensive fiber optic network infrastructure, it provides Internet with the highest speed available on the market, up to 1,000 MB, cable television and high definition voice services to more than 4 million homes and businesses throughout the country.
Through its human team, agile, with challenging and daring thinking, it promotes innovation in everything it does and demonstrates its commitment to each of the Dominicans in providing them with access to technology to boost their growth opportunities.
*2023 Global Travel Trends Report
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514293879/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom